Summary

Overview
Global Zoonotic Disease Treatment market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Zoonotic diseases such as rabies, lyme disease, bird flu, hepatitis, and plague are a few which are prevalent in certain parts of the world. These Zoonotic infections are caused by bacteria, viruses, parasites, fungi, nematodes, and rodents and spread through contaminated food and water, direct and indirect contact with animals. According to WHO, there are more than 200 known types of zoonotic infections.
Market Dynamics: Drivers & Restraints
Increasing awareness about zoonotic diseases
Zoonotic diseases are transmitted from animals to humans which is increasing the global health burden. According to the National Center for Biotechnology Information, 2023, Zoonotic diseases are responsible for 2.5 billion human cases globally and approximately 2.7 million deaths annually. They are responsible for more than 60% of all recognized human diseases and 75% of emerging infectious diseases.
Due to the zoonotic disease prevalence, government organizations are launching programs and campaigns to raise awareness among people. For instance, in July 2023, WHO launched the “One Life, one Liver” campaign on World Hepatitis Day.
In July 2023, SMC (Srinagar Municipal Corporation) launched Animal Birth Control and anti-rabies vaccination program. The initiative aims to curb the overpopulation of stray dogs while eliminating the threat of rabies transmission within the community
In January 2024, according to the Food and Agriculture Organization launched a program "Enhancing Animal Health & One Health Capacities to Mitigate Zoonotic Diseases and Antimicrobial Resistance Risks & Threats" in collaboration with the United States Agency for International Development (USAID) Malawi, The Malawi Government.
Limited access to healthcare
Healthcare access such as services like prevention, diagnosis, treatment, and management of zoonotic diseases in low-income countries is very limited. It creates a barrier to obtaining proper medical care for deadly diseases like Lyme disease, hepatitis, etc. According to the Rural Health Information Hub, as of September 2022, 65.6% of Primary Care Health Professional Shortage Areas (HPSAs) were located in rural areas. Furthermore, poor health literacy, workforce shortages, social stigma, and privacy issues limit access to healthcare services in rural areas.
Segment Analysis
The global zoonotic disease treatment market is segmented based on disease type, causative agent, drug type, end user and region.
Vaccines Drug Type is Expected to Dominate Market
Increasing strategies by key companies and government organizations are expected to drive the market. Due to an increase in the vaccination drives conducted in low-income countries by government organizations, there is growing awareness of vaccines and other drugs.
For instance, in October 2023, UNICEF signed a deal with Serum Life Sciences for 2024 – 2028 for a secure supply of the world’s second malaria vaccine, R21/Matrix-M. The deal is a major milestone towards meeting the high demand for doses of new vaccines against malaria
Furthermore, in January 2024, Indian Immunologicals Ltd (IIL) launched India’s ‘first’ indigenously developed Hepatitis A vaccine, Havisure. Also, in March 2023, Cadila Pharma's novel three-dose rabies vaccine ThRabis under trial for use in children.
Geographical Analysis
North America is Expected to Dominate the Global Market
North America is expected to hold the largest share in the market owing to the rapid urbanization, and expansion of healthcare facilities for the development of new drugs and vaccines. Technological advancements also play a huge role in the zoonotic disease treatment market.
Major key players such as Merck & Co., Inc., Johnson & Johnson, etc are continuously working on the development of new drugs and vaccines for diseases like rabies, hepatitis, etc to eradicate the diseases from the US. Due to the presence of cutting-edge infrastructure, rise in government policies to decrease the burden of zoonotic diseases, and increasing investments in R&D in North America, the market is expected to hold the largest share.
Market Segmentation
By Disease Type
• Rabies
• Hepatitis
• Lyme disease
• Plague
• Malaria
• Others
By Causative Agent
• Bacteria
• Virus
• Nematodes
• Rodents
• Ticks
• Others
By Drug Type
• Antifungal medication
• Antibacterial medication
• Antibiotics
• Others
By End Users
• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In November 2023, Indian Immunologicals Ltd (IIL) launched the measles and rubella vaccine for children.
• In March 2023, GSK plc and SCYNEXIS, Inc. agreed to commercialize Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC (RVVC).
Competitive Landscape
The major global players in the zoonotic disease treatment market include Merck & Co., Inc, GlaxoSmithKline plc, Pfizer, Inc., Sanofi S.A., Novartis AG, Johnson & Johnson, AstraZeneca Plc, Zydus Lifesciences Limited, F Hoffmann-La Roche Inc., Eli Lilly and Company among others.
Why Purchase the Report?
• To visualize the global zoonotic disease treatment market segmentation based on disease type, causative agent, drug type, end user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of zoonotic disease treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global zoonotic disease treatment market report would provide approximately 65 tables,751 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Causative Agent
3.3. Snippet by Drug Type
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing awareness about zoonotic diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Limited access to healthcare
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. Epidemiology
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Rabies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Hepatitis
7.4. Lyme disease
7.5. Plague
7.6. Malaria
7.7. Others
8. By Causative Agent
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Causative Agent
8.1.2. Market Attractiveness Index, By Causative Agent
8.2. Bacteria*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Virus
8.4. Nematodes
8.5. Rodents
8.6. Ticks
8.7. Others
9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.1.2. Market Attractiveness Index, By Drug Type
9.2. Antifungal medication*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Antibacterial medication
9.4. Antibiotics
9.5. Vaccines
9.6. Others
10. By End Users
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals and Clinics*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Causative Agent
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Causative Agent
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Causative Agent
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Causative Agent
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Causative Agent
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Merck & Co., Inc*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. GlaxoSmithKline plc
13.3. Pfizer, Inc.
13.4. Sanofi S.A.
13.5. Novartis AG
13.6. Johnson & Johnson
13.7. AstraZeneca Plc
13.8. Zydus Lifesciences Limited
13.9. F Hoffmann-La Roche Inc.
13.10. Eli Lilly and Company LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us